|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lewis DR, Check DP, Caporaso NE, Travis WD
and Devesa SS: US lung cancer trends by histologic type. Cancer.
120:2883–2892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bild AH, Yao G, Chang JT, Wang Q, Potti A,
Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al:
Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature. 439:353–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang P, Cheng CL, Chang YH, Liu CH, Hsu
YC, Chen JS, Chang GC, Ho BC, Su KY, Chen HY and Yu SL: Molecular
gene signature and prognosis of non-small cell lung cancer.
Oncotarget. 7:51898–51907. 2016.PubMed/NCBI
|
|
6
|
Tan Q, Wang G, Huang J, Ding Z, Luo Q, Mok
T, Tao Q and Lu S: Epigenomic analysis of lung adenocarcinoma
reveals novel DNA methylation patterns associated with smoking.
Onco Targets Ther. 6:1471–1479. 2013.PubMed/NCBI
|
|
7
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilkerson MD, Yin X, Hoadley KA, Liu Y,
Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski
MA, et al: Lung squamous cell carcinoma mRNA expression subtypes
are reproducible, clinically important, and correspond to normal
cell types. Clin Cancer Res. 16:4864–4875. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raponi M, Zhang Y, Yu J, Chen G, Lee G,
Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y and Beer DG:
Gene expression signatures for predicting prognosis of squamous
cell and adenocarcinomas of the lung. Cancer Res. 66:7466–7472.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lawson MH, Cummings NM, Rassl DM, Vowler
SL, Wickens M, Howat WJ, Brenton JD, Murphy G and Rintoul RC: Bcl-2
and β1-integrin predict survival in a tissue microarray of small
cell lung cancer. Br J Cancer. 103:1710–1715. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dutta C, Day T, Kopp N, van Bodegom D,
Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, et
al: BCL-2 suppresses PARP1 function and nonapoptotic cell death.
Cancer Res. 72:4193–4203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janumyan Y, Cui Q, Yan L, Sansam CG,
Valentin M and Yang E: G0 function of BCL2 and BCL-xL requires BAX,
BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX
and BAK in quiescence regulation. J Biol Chem. 283:34108–34120.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Daniel JC and Smythe WR: The role of Bcl-2
family members in non-small cell lung cancer. Semin Thorac
Cardiovasc Surg. 16:19–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bouchalova K, Kharaishvili G, Bouchal J,
Vrbkova J, Megova M and Hlobilkova A: Triple negative breast
cancer-BCL2 in prognosis and prediction. Review. Curr Drug Targets.
15:1166–1175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Renouf DJ, Wood-Baker R, Ionescu DN, Leung
S, Masoudi H, Gilks CB and Laskin J: BCL-2 expression is prognostic
for improved survival in non-small cell lung cancer. J Thorac
Oncol. 4:486–491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martinez-Arribas F, Alvarez T, Del Val G,
Martín-Garabato E, Núñez-Villar MJ, Lucas R, Sánchez J, Tejerina A
and Schneider J: Bcl-2 expression in breast cancer: A comparative
study at the mRNA and protein level. Anticancer Res. 27:219–222.
2007.PubMed/NCBI
|
|
17
|
Martin B, Paesmans M, Berghmans T, Branle
F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout
JM, et al: Role of Bcl-2 as a prognostic factor for survival in
lung cancer: A systematic review of the literature with
meta-analysis. Br J Cancer. 89:55–64. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shibata Y, Hidaka S, Tagawa Y and Nagayasu
T: Bcl-2 protein expression correlates with better prognosis in
patients with advanced non-small cell lung cancer. Anticancer Res.
24:1925–1928. 2004.PubMed/NCBI
|
|
19
|
Porebska I, Kosacka M, Wyrodek E and
Jankowska R: Expression of p53, bcl-2 and nm23 proteins in squamous
cell lung cancer. Pneumonol Alergol Pol. 77:131–137. 2009.(In
Polish). PubMed/NCBI
|
|
20
|
Kim YC, Park KO, Kern JA, Park CS, Lim SC,
Jang AS and Yang JB: The interactive effect of Ras, HER2, P53 and
Bcl-2 expression in predicting the survival of non-small cell lung
cancer patients. Lung Cancer. 22:181–190. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Wang S, Wang L, Wang R, Chen S,
Pan B, Sun Y and Chen H: Prognostic value of Bcl-2 expression in
patients with non-small-cell lung cancer: A meta-analysis and
systemic review. Onco Targets Ther. 8:3361–3369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cancer Genome Atlas Research Network:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baty F, Facompré M, Kaiser S, Schumacher
M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, et
al: Gene profiling of clinical routine biopsies and prediction of
survival in non-small cell lung cancer. Am J Respir Crit Care Med.
181:181–188. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Zhao W and Zhou X: Integration of
genomic data analysis for demonstrating potential targets in the
subgroup populations of squamous cell lung cancer patients.
Oncotarget. Jun 15–2016.DOI: 10.18632/oncotarget.10072.
|
|
26
|
Gentles AJ, Newman AM, Liu CL, Bratman SV,
Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The
prognostic landscape of genes and infiltrating immune cells across
human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pøhl M, Olsen KE, Holst R, Ditzel HJ and
Hansen O: Tissue microarrays in non-small-cell lung cancer:
Reliability of immunohistochemically-determined biomarkers. Clin
Lung Cancer. 15:222–230.e3. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Micke P, Mattsson JS, Djureinovic D, Nodin
B, Jirström K, Tran L, Jönsson P, Planck M, Botling J and
Brunnström H: The impact of the 4th edition of the WHO
classification of lung tumours on histological classification of
resected pulmonary NSCCs. J Thorac Oncol. 11:862–872. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Q, Hou J, Hu Z, Gu B and Shi Y:
Multiple mutations of lung squamous cell carcinoma shared common
mechanisms. Oncotarget. 7:79629–79636. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Der SD, Sykes J, Pintilie M, Zhu CQ,
Strumpf D, Liu N, Jurisica I, Shepherd FA and Tsao MS: Validation
of a histology-independent prognostic gene signature for
early-stage, non-small-cell lung cancer including stage IA
patients. J Thorac Oncol. 9:59–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK,
Moon HG, Han W, Park IA and Noh DY: Prognostic influence of BCL-2
expression in breast cancer. Int J Cancer. 131:E1109–E1119. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng Y, Wang L, Qing Y, Li C, Ren T, Li Q,
Li M, Zhang S, Shan J, Wang G, et al: Polymorphisms of BCL2 and BAX
genes associate with outcomes in advanced non-small cell lung
cancer patients treated with platinum-based chemotherapy. Sci Rep.
5:177662015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh K and Briggs JM: Functional
implications of the spectrum of BCL2 mutations in lymphoma. Mutat
Res Rev Mutat Res. 769:1–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
